MOTS-c is NOT appropriate for treating anovulatory cycles in reproductive-age women
MOTS-c is an experimental mitochondrial-derived peptide with no established role in human fertility treatment, and standard evidence-based ovulation induction should be used instead.
Current Evidence on MOTS-c
The only available evidence on MOTS-c and reproduction comes from a 2024 animal study 1 showing that central infusion of MOTS-c in rats increased GnRH expression and reproductive hormone levels (LH, FSH, testosterone). This is purely preclinical research with:
- No human studies
- No safety data in women
- No efficacy data for ovulation induction
- No regulatory approval for fertility treatment
Using MOTS-c clinically would be experimental and inappropriate given the availability of proven, safe alternatives.
Standard Ovulation Induction Options
First-Line Treatment
Clomiphene citrate (or letrozole) is the recommended first-line treatment for anovulatory infertility 2. The Endocrine Society guideline explicitly states this as a strong recommendation.
- Clomiphene citrate: Traditional first-line agent with cumulative pregnancy rates reaching 71-78% over 2 years 3
- Letrozole: A large NIH trial (n=750) demonstrated marked superiority in live birth rates compared to clomiphene in PCOS patients with comparable safety 2. This aromatase inhibitor is increasingly preferred as first-line therapy 4
Both drugs work by modulating estrogen action to induce ovulation and are appropriate for women with normal FSH, normal prolactin, and adequate estrogen levels 5.
Second-Line Options
For clomiphene-resistant patients:
- Metformin plus clomiphene: In clomiphene-resistant women, this combination led to higher live birth rates than clomiphene alone (RR 6.4; 95% CI 1.2-35) 2
- Gonadotropin therapy: Effective but carries higher risk of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS), particularly in PCOS patients 2, 6
- Laparoscopic ovarian drilling: Achieves conception rates equivalent to gonadotropins with fewer multiple births 7
Adjunctive Therapy
Metformin has limited standalone efficacy for improving live birth rates 2 but may be useful:
- As adjuvant therapy to prevent OHSS in women undergoing IVF 2
- More effective in obese versus non-obese women 2
- For metabolic management in PCOS patients with insulin resistance 4
Specialized Situations
- Hyperprolactinemia: Bromocriptine is specifically indicated 5
- Hypogonadotropic hypogonadism: Pulsatile GnRH or gonadotropin therapy 5, 7
Critical Pitfalls
Multiple pregnancy risk: Ovulation induction carries 5% multiple pregnancy risk with clomiphene and higher with gonadotropins 2. Low-dose protocols and careful monitoring are essential.
Confirming ovulation: Regular bleeding does not guarantee ovulation—26% of athletes in one study had anovulatory cycles despite regular menses 8. Progesterone levels must reach ≥16 nmol/L mid-luteal phase to confirm ovulation.
Lifestyle modification first: In PCOS patients with impaired glucose tolerance, lifestyle modification (diet and exercise) should precede pharmacological treatment 2.
Treatment duration: The lengthy treatment period with ovulation induction (up to 2 years for optimal cumulative rates) versus more efficient IVF approaches (83% cumulative rate over 3 cycles) is an important counseling point 3.